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ABSTRACT
Crohn disease (CD) and ulcerative colitis (UC) are chronic forms of inflammatory 
bowel disease (IBD) whose pathogenesis is only poorly understood. Estrogens have 
a complex role in inflammation and growing evidence suggests that these hormones 
may impact IBD pathogenesis. Here, we demonstrated a significant reduction (p < 
0.05) of estrogen receptor (ER)β expression in peripheral blood T lymphocytes from 
CD/UC patients with active disease (n = 27) as compared to those in remission (n 
= 21) and healthy controls (n = 29). Accordingly, in a subgroup of CD/UC patients 
undergoing to anti-TNF-α therapy and responsive to treatment, ERβ expression was 
higher (p < 0.01) than that observed in not responsive patients and comparable to 
that of control subjects. Notably, ERβ expression was markedly decreased in colonic 
mucosa of CD/UC patients with active disease, reflecting the alterations observed in 
peripheral blood T cells. ERβ expression inversely correlated with interleukin (IL)-6 
serum levels and exogenous exposure of both T lymphocytes and intestinal epithelial 
cells to this cytokine resulted in ERβ downregulation. These results demonstrate that 
the ER profile is altered in active IBD patients at both mucosal and systemic levels, 
at least in part due to IL-6 dysregulation, and highlight the potential exploitation of 
T cell-associated ERβ as a biomarker of endoscopic disease activity.
INTRODUCTION
Crohn disease (CD) and ulcerative colitis (UC) 
are chronic forms of inflammatory bowel disease (IBD) 
arising from the combined effects of genetic susceptibility, 
environmental influences, intestinal dysbiosis, and innate 
and adaptive immune system dysregulation, leading to 
chronic inflammation and subsequent tissue damage [1, 
2]. TNF-α, a molecule with a broad spectrum of activity, 
including costimulation of lymphocyte inflammatory 
functions and direct disruption of intestinal epithelial 
barrier integrity, has a well-established pathological role 
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in IBD and has been successfully exploited as a target 
for therapeutic intervention [3]. However, subgroups 
of IBD patients fail to respond or lose response to this 
drug indicating that the immune networks in the inflamed 
mucosa are complex and subjected to multiple layers of 
regulation by still unrecognized factors [3]. 
Growing evidence from epidemiological and 
experimental studies suggests a role for estrogens, 
particularly 17β estradiol, in IBD pathogenesis [4-14]. 
Estrogens have been shown to finely regulate inflammation 
[15] and have been implicated in the modulation of several 
immune-mediated diseases [16, 17]. Most of their effects 
are mediated by two intracellular receptors, i.e, estrogen 
receptor (ER)α and ERβ, which function as ligand-
activated nuclear transcription factors producing genomic 
effects [15]. ERs are expressed in different cell types 
including immune cells [18-21] and the presence of one 
ER subtype over the other may change estrogen effects, 
promoting or dampening inflammation [15].
ERβ is the predominant ER subtype in colon tissue, 
where it plays a fundamental role in growth, organization 
and maintenance of normal epithelial architecture [12, 22, 
23]. Interestingly, reduced ERβ mRNA expression and 
increased gut permeability were found to precede the onset 
of colitis in mouse models of intestinal inflammation [12]. 
Additionally, ERβ knockout mice developed a clinically 
more severe colitis as compared to wild-type littermates 
[13]. In keeping with these findings, beneficial effects of 
ERβ agonists as well as estrogens have been reported in 
different models of chronic colitis [9-11, 14]. There is also 
evidence that estrogens can modulate disease severity in 
IBD patients [4-6]. However, ER expression in human 
IBD and its possible correlation with disease activity 
have been till now poorly investigated, with the exception 
of one study by Looijer-van Langen et al. [12] showing 
decreased ERβ mRNA levels in colonic biopsies from 
CD patients in relapse, but not in remission. Notably, UC 
and CD are associated with an increased risk of colorectal 
cancer (CRC) that appears to increase with the duration, 
severity and anatomic extent of colonic inflammation 
[24, 25]. In this respect, growing data support a role for 
estrogen/ER in the initiation and progression of CRC, and 
establish that protective effects of estrogen are exerted 
through ERβ [26-28].
In this study we report IBD-associated alterations 
of ER expression profile both in peripheral blood T 
lymphocytes and in colonic mucosa and their relationship 
with the clinical characteristics of the studied population. 
We also identified interleukin (IL)-6 as an unrecognized 
regulator of ER expression in circulating T cells and 
intestinal epithelium.
RESULTS AND DISCUSSION
ERβ expression is downregulated in peripheral 
blood T lymphocytes from active IBD patients
We evaluated by flow cytometry the intracellular 
expression of ERα and ERβ in peripheral blood T 
lymphocytes from 48 patients with IBD (CD, n = 26 and 
UC, n = 22) and 29 age/sex matched healthy controls 
(HC). The demographic and clinical characteristics of IBD 
patients are summarized in Table 1. A significant increase 
of ERα and a concomitant decrease of ERβ expression 
were observed in T lymphocytes from IBD patients as 
compared to HC, whereas no differences were detected 
between CD and UC patients (Figure 1A and 1B). Similar 
results were obtained when purified CD4+ and CD8+ T 
cells were analyzed separately (data not shown). For both 
ERα and ERβ expression, no significant associations 
were found with the epidemiological data (sex, age) of 
the patient population. To estimate whether ER expression 
level reflects disease activity, the patient population was 
divided into 2 groups according to the endoscopic activity 
at the time of sampling, i.e., patients with active disease 
and those in remission (see Materials and Methods and 
Table 1 for details). Although ERα expression was not 
significantly different in T cells from patients in remission 
and those with active disease (Figure 1C), a significantly 
lower expression of ERβ was found in T cells from CD/
Table 1: Demographic and clinical characteristics of the study sample
CD UC
Patients, n of patients 26/48 22/48
Age (years), median (range) 45 (19-70) 44 (19-68)
Women/men 11/15 10/12
Endoscopic remissiona, n of patients (%) 12 (46) 9 (41)
Current drug therapy, n of patients (%)
5-aminosalicylic acid 8 (31) 10 (45)
Systemic corticosteroid 2 (7) 2 (9)
Anti-TNFα (Infliximab/Adalimumab) 12 (46) 7 (32)
aCD: Crohn's Disease Endoscopic Index of Severity (CDEIS, remission when score < 3); post-operative CD: Rutgeerts score 
(remission when score = i0); UC: Mayo endoscopic sub-score (remission when score = 0).
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UC patients with active disease as compared to those in 
remission (Figure 1D). 
Although ERs have been shown to finely regulate 
inflammation [15], this is the first demonstration of a 
specific alteration of ER profile in IBD. The current 
diagnosis and management of IBD is based on clinical 
and endoscopic criteria [29]. More specifically, as routine 
clinical assessment is often inaccurate with respect to 
endoscopic activity [30], colonoscopy represents the gold 
standard technique for the evaluation of disease severity. 
However, due to the complexity and invasiveness of this 
practice, there is a pressing need for new non-invasive 
biomarkers to improve disease activity detection, in 
order to better determine prognosis and to monitor drug 
response. In this regard, the strong association between 
lymphocyte ERβ levels and endoscopic disease activity 
observed in our study points to this receptor as a potential 
prognostic biomarker for IBD.
Interestingly, blood T lymphocytes from a 
subgroup of CD/UC patients in ongoing treatment with 
anti-TNF-α (infliximab or adalimumab: 12/26 CD and 
7/22 UC) showed significantly different expression of 
ERβ according to drug response, as monitored by the 
endoscopic activity. Specifically, responsive patients 
(n = 8) expressed higher levels of ERβ as compared 
to unresponsive patients (n = 11) (Figure 1E). The 
expression of ERα was found to be not significantly 
different between these 2 groups of patients (Figure 1F). 
As response to therapy has been established on the basis 
of disease remission at the endoscopic level, our findings 
Figure 1: Intracellular ER expression in peripheral blood T lymphocytes from CD/UC patients. A.-D. Intracellular ERα 
and ERβ expression levels evaluated by flow cytometry in T cells from CD/UC patients, considered as a whole (n = 48) or divided in 
patients in remission (n = 21) and those with active disease (n = 27) according to the endoscopic activity, and from healthy controls (HC; 
n = 29). E., F. Intracellular ER expression evaluated in T cells from a subgroup of CD/UC patients in ongoing treatment with anti-TNF-α 
(n = 19), divided in responsive (n = 8) and unresponsive (n = 11) patients. Values of ER/isotype control mean fluorescence intensity ratio 
(rMFI) are reported (mean ± SEM is shown for each group). Statistical differences were calculated by the Mann-Whitney U test. *p < 
0.05 ; ** p < 0.01; *** p < 0.001. NS, nonsignificant; rCD/UC, CD/UC patients in endoscopic remission; aCD/UC, CD/UC patients with 
endoscopic activity.
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further strengthen the role of T cell-associated ERβ as a 
systemic marker of intestinal disease activity. Additionally, 
the association found between anti-TNF-α response and 
normal ERβ levels in blood T lymphocytes suggests 
that ERβ may represent a candidate predictive marker 
to assess responsiveness to biological therapy. However, 
longitudinal studies including subjects analyzed before 
and after the initiation of anti-TNF-α therapy are needed 
to provide conclusive evidence for a strict association 
between anti-TNF-α response and ERβ rescue.
ERβ dysregulation in peripheral blood reflects 
that observed in intestinal mucosa
It has been previously shown that the accumulation 
of ERβ transcripts is decreased in intestinal mucosa 
samples from IBD patients as compared to controls [12]. 
To assess the expression of ERβ protein in intestinal 
mucosa of IBD patients and to evaluate whether this 
expression reflects that observed in the blood, ERβ was 
also analyzed in whole colonic mucosa from 19 out of 48 
CD/UC patients and 10 age/sex matched HC. As shown in 
Figure 2A, ERβ was highly expressed in normal colonic 
mucosa, where a positive staining could be observed in 
both epithelial cells and lamina propria lymphocytes. 
Interestingly, a consistent reduction of ERβ expression 
was found in intestinal mucosa from CD/UC subjects with 
active disease (Figure 2B and 2C) but not from those in 
remission (Figure 2E and 2F). In particular, a reduction 
of both epithelial cell- and lymphocyte-associated ERβ 
levels could be appreciated in inflamed mucosa (Figure 
2B and 2C). Consistent with previous reports [26, 31, 32], 
neoplastic mucosa explanted from patients with colon 
adenocarcinoma (n = 5) displayed very low levels of ERβ 
expression (Figure 2D). 
These results provide the first evidence that, in 
human colon, ERβ is markedly reduced in both CD and 
UC patients and the extent of its expression reflects disease 
activity. Of note, ERβ down-regulation in the colon tissue 
parallels that observed in blood T lymphocytes, further 
strengthening the role of T cell-associated ERβ as a 
systemic marker of intestinal disease activity. Moreover, 
the finding that colonic ERβ expression inversely 
Figure 2: ERβ expression in colonic mucosa from CD/UC patients. Light microscopic micrographs of typical ERβ expression 
(brown staining) in normal colonic mucosa A., colonic mucosa from UC B. or CD C. patients in the active phase of disease, colonic mucosa 
from UC E. or CD F. patients in remission, and colon adenocarcinoma D.. Arrays indicate the disrupted or regenerating epithelium typical 
of UC mucosa in the active phase of disease B. and in remission E., respectively. The asterisk indicates the typical fistula distinguishing CD 
mucosa C.. One representative image of each group (UC, n = 10; CD, n = 9; HC, n = 10; colon adenocarcinoma patients, n = 5) is shown 
(original magnifications x20).
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correlates with cancer development/progression [26, 31, 
32], together with our results, point to ERβ as a major 
regulator of intestinal epithelium integrity also in the 
human system and suggest a role for this receptor in 
maintaining homeostasis. Of note, IBD represent a risk 
factor for CRC development [24, 25], and inflammation-
associated early ERβ down-regulation might be one of the 
factors linking chronic intestinal diseases to neoplastic 
transformation.
Figure 3: Plasma cytokine profile of CD/UC patients and effect of IL-6 on ERβ expression in peripheral blood T 
lymphocytes and intestinal epithelial cells. A.-C. Cytokine plasma levels from 41 CD/UC patients (n = 25 with active disease, n = 16 
in remission) and 17 HC. Mean ± SEM is shown for each group. D. Correlation between plasma levels of IL-6 and ERβ expression (shown 
as ERβ/isotype control mean fluorescence intensity ratio, rMFI) in T lymphocytes from CD/UC patients determined by the Spearman’s 
rank correlation test. R, Spearman’s rho. E. Intracellular ERβ expression evaluated by flow cytometry in T lymphocytes from HC exposed 
for 72 h to the indicated cytokines. Data are expressed as percentage relative to untreated cells (mean ± SEM of 5 independent experiments 
is shown). F., G. Western blot analysis of ERβ expression in differentiated Caco-2 cells stimulated with IL-6 at either apical or basolateral 
side. Data from one representative experiment out of three are shown F.. Densitometry analysis of protein levels relative to β-actin is also 
shown G.. Values are expressed as mean ± SEM. Statistical differences were calculated by the Mann-Whitney U test. *p < 0.05 ; ** p < 
0.01; *** p < 0.001. rCD/UC, CD/UC patients in endoscopic remission; aCD/UC, CD/UC patients with endoscopic activity.
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IL-6 plasma levels inversely correlate with ERβ 
expression and exogenous exposure of both 
lymphocytes and intestinal epithelial cells to 
recombinant IL-6 results in ERβ downregulation
The unbalanced expression of ERα and ERβ, 
exhibiting pro- versus anti-inflammatory features, 
respectively, suggests that a switch toward ER-mediated 
inflammatory responses occurs in CD/UC patients. 
Whether the alterations of ER and ER-induced responses 
contribute to establish or are a consequence of the 
chronic inflammatory process observed in these subjects 
is currently unknown. The finding that a similar ER 
regulation occurred in both CD and UC, which exhibit 
different localization, endoscopic findings and histological 
features, would support the latter hypothesis.
The analysis of soluble immune mediators in plasma 
samples from CD/UC patients revealed significantly higher 
levels of the pro-inflammatory cytokines IL-6, TNF-α and 
IFN-γ in subjects with active disease as compared to those 
in remission (Figure 3A-3C). Interestingly, a significant 
inverse correlation was found between ERβ expression 
and plasma levels of IL-6 (Figure 3D) but not those of 
TNF-α and IFN-γ (R = -0.10, p = 0.58, and R = -0.07, p 
= 0.69, respectively, data not shown). No correlation was 
found between ERα expression and plasma cytokine levels 
(data not shown).
Based on these results, the effect of exogenous 
administration of IL-6 on ERβ expression was 
investigated. As shown in Figure 3E, exposure of control 
blood T lymphocytes to IL-6 significantly reduced ERβ 
expression, whereas TNF-α and IFN-γ did not exert any 
effect. Conversely, ERα levels were not significantly 
modulated by these cytokines (data not shown). To assess 
whether intestinal ERβ expression could be regulated as a 
result of inflammatory cytokine stimulation, Caco-2 cell-
derived normal epithelium was exposed to IL-6 at either 
apical or basolateral sides. Consistent with the results 
obtained in T cells, IL-6 was found to downregulate ERβ 
expression in intestinal epithelial cells. Notably, this effect 
was observed when IL-6 was added to the basolateral but 
not to the apical side (Figure 3F and 3G), thus resembling 
the cross-talk between intestinal epithelium and lamina 
propria immune cells occurring in vivo [33]. 
Although the mechanism(s) underlying ERβ 
regulation remain to be further elucidated, our results 
show that the pro-inflammatory cytokine IL-6, 
whose levels we found increased in serum from IBD 
patients with active disease, contributes to regulate ER 
expression in T lymphocytes and in in vitro-generated 
intestinal epithelium. IL-6 has been recently reported to 
negatively regulate ERβ expression in ovarian cancer 
cell lines [34]. To the best of our knowledge, this is the 
first demonstration that this cytokine can regulate ERβ 
expression in intestinal epithelium and blood T cells, 
suggesting that the inflammatory microenvironment of 
IBD patients plays a role in controlling the ERα/ERβ 
balance. In keeping with this hypothesis, the potential of 
IL-6 targeting as a therapeutic strategy in IBD is under 
investigation [35].
A deeper characterization of factors and mechanisms 
controlling ER expression and function may increase our 
knowledge on the pathogenesis of IBD and open new 
perspectives for the comprehension and management of 
the disease. Further analysis using ERα and ERβ selective 
agonists will allow to more deeply investigate the ER-
mediated responses elicited in chronic inflammatory 
conditions, and to study the potential role of ER as 
therapeutic target. Reliable biomarkers of disease activity 
as well as of response to therapy are not yet available in 
IBD. Thus, identifying new factors/mechanisms that are 
dysregulated in IBD patients may open new perspectives 
for the comprehension of disease pathogenesis and 
clinical management. Overall, our results indicate that a 
better understanding of the role of ERs may advance our 




Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board. All the subjects included were 
provided with complete information about the study and 
asked to sign an informed consent.
Patients and biological samples
Biological samples were obtained from patients with 
documented CD (n = 26) or UC (n = 22) attending to the 
Digestive Endoscopy Unit (Catholic University, Rome, 
Italy), the Gastroenterology and Digestive Endoscopy 
(Nuovo Regina Margherita Hospital, Rome, Italy), and 
the IBD Unit (Complesso Integrato Columbus, Catholic 
University, Rome, Italy). Endoscopic biopsies from 5 
patients with colon adenocarcinoma were obtained from 
the Histopathology Complex Unit (Santo Spirito Hospital, 
Rome, Italy). Twenty-nine healthy controls (HC) matched 
for age and sex made up a control group. The exclusion 
criteria were: clinical evidence of active infection, recent 
(within 14 days) use of antibiotics, pregnancy, hormone-
based therapy, and treatment with corticosteroids 
(methylprednisolone or equivalents ) at doses > 20 mg/day. 
Patients undergoing anti-TNF-α therapy were analyzed 
after at least 6 months from the initiation of therapy and 
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blood ER expression was determined the week before the 
next anti-TNF-α administration. Endoscopic results were 
assessed according to the Crohn’s Disease Endoscopic 
Index of Severity (CDEIS, remission when score < 3) 
[36] for CD, the Rutgeerts score (remission when score = 
i0) [37] for post-operative CD, and the Mayo endoscopic 
sub-score (remission when score = 0) [38] for UC. Blood 
samples were drawn at the time of obtaining peripheral 
vein access for the endoscopic procedure. Plasma were 
frozen soon after collection and stored at -80°C until used. 
Endoscopic biopsies were taken from colon/ileum tissue 
of IBD patients, whereas surgical specimens of colonic 
mucosa, from both neoplastic and adjacent ( > 5 cm distal) 
macroscopically non-neoplastic regions, were obtained 
from subjects with colon adenocarcinoma. Intestinal 
mucosa was fixed in 10% formalin and stored for further 
processing.
Isolation of peripheral blood mononuclear cells 
and cell culture conditions
Peripheral blood mononuclear cells were isolated 
by Ficoll-Hypaque density-gradient centrifugation. 
Untouched T cells were subsequently separated using the 
Pan T Cell isolation Kit II (Miltenyi Biotec, Bergisch-
Gladbach, Germany). The purity of recovered cells, 
assessed by flow cytometer, was ≥ 97%. For ER analysis, 
cells were processed soon after isolation. For cytokine 
stimulation, T cells isolated from HC were seeded in 
RPMI-1640 medium without phenol red (GIBCO BRL, 
Grand Island, NY, USA) supplemented with 10% charcoal-
stripped fetal bovine serum (FBS, Euroclone, Pero, Milan, 
Italy), 2mM glutamine (Sigma, St. Louis, MO, USA) 50 
μg/ml gentamycin (Sigma), and exposed for 72 hours to 
IL-6 or TNF-α (Peprotech, Rocky Hill, NJ, USA; 50 ng/
ml) or IFN-γ (Peprotech, 500 IU/ml) before ER analysis. 
The 72 hour time point as well as the concentrations used 
were chosen on the basis of preliminary time course and 
dose-response experiments showing that these conditions 
were those at which the highest changes of ER expression 
could be detected.
Flow cytometry
Intracellular phenotyping of T cells was performed 
by flow cytometry as previously described [21]. FITC-
conjugated rabbit anti-human ERα antibody (Ab, clone 
MC-20) or mouse anti-human ERβ (clone 1531) Ab, both 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), 
were used. Equal amounts of appropriate isotype controls 
(Santa Cruz Biotechnology) were used. Anti-human 
ERβ Ab was visualized by fluorescein isothiocyanate-
conjugated F(ab’)2 fragment secondary Ab (Abcam, 
Cambridge, UK). Allophycocyanin conjugated anti-CD3, 
phycoerythrin conjugated anti-CD4, peridinin chlorophyll 
protein-conjugated anti-CD8 monoclonal Abs (all from 
BD Biosciences, San Jose, CA, USA) were also used to 
identify ERα and ERβ expression in lymphocyte subsets. 
Acquisition was performed on a FACSCalibur cytometer 
(BD Biosciences) and 50,000 events per sample were 
run. Data were analyzed using the Cell Quest Pro (BD 
Biosciences) software.
Quantification of plasma cytokine/chemokine 
levels
The analysis of cytokine content in plasma samples 
of randomly selected HC and IBD patients was performed 
by using the Bio-Plex Pro Human Cytokine 27-plex Assay 
(Bio-Rad Laboratories, Hercules, CA, USA) according to 
the manufacturer’s instructions. This assay was able to 
concomitantly detect the following cytokines, chemokines 
and growth factors: IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-
6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-
17, Basic FGF, Eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, 
MCP-1 (MCAF), MIP-1α, MIP-1β, PDGF-BB, RANTES, 
TNF-α, VEGF. The assay was performed at the Facility 
for Complex Protein Mixture (CPM) Analysis (Istituto 
Superiore di Sanità, Rome, Italy).
Immunohistochemistry analysis
Intestinal mucosa sections were mounted on to 
superfrost microscope slides and immunostaining of ERβ 
was performed. Mouse anti-human ERβ Ab (clone 14C8, 
Abcam) was applied at a dilution of 1:200 for 60 minutes 
at 37°C. Antigen retrieval was performed with Cell 
Conditioning (CC1, Ventana Medical Systems, Illkirch, 
France) for 60 minutes at 98°C. The Ab reactions were 
revealed using the ultraView Universal DAB (Ventana 
Medical Systems). ERβ staining of neoplastic mucosa 
from subjects with colon adenocarcinoma was also 
performed, whereas adjacent normal mucosa ( > 5 cm 
distal from the neoplastic lesion) was used as a positive 
control. Sections incubated after the omission of the 
primary Ab were used as negative controls. The sections 
were counterstained with haematoxylin, dehydrated and 
mounted on glass coverslips. All samples were observed 
and photographed with a Zeiss Axiovert microscope.
Caco-2 cell based model of intestinal epithelium 
and western blot analysis of ERβ expression
Polarized human intestinal epithelium was 
obtained by culturing Caco-2 cells (ATCC #HTB-37) on 
polycarbonate-coated trans-well chambers (8x104 cell/
cm2) in high glucose Dulbecco’s Modified Eagle Medium 
(DMEM) plus 10% FBS and nonessential amino acids 
for 21 days as previously described [39]. Trans epithelial 
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electrical resistance was monitored throughout the 
differentiation period. Differentiated cell cultures were 
then stimulated for 24 hours with recombinant IL-6 (50 
ng/ml) at either apical or basolateral sides, then harvested 
and lysed in RIPA buffer. Intracellular ERβ expression 
analysis was performed by western blot as previously 
described [21], using a mouse anti-human ERβ Ab (clone 
1531, Santa Cruz Biotechnology). To ensure the presence 
of equal amounts of protein, the membranes were re-
probed with a rabbit anti-human β-actin Ab (Sigma).
Statistics
The Mann-Whitney U test was used for comparisons 
between different groups. Correlations were evaluated 
using Spearman’s rank correlation test. Linear regression 
analysis was performed to display a best fit line to the 
data. Statistical analyses were performed using GraphPad 
Prism 5 software. All tests were 2-sided and a p value < 
0.05 was considered statistically significant.
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